Metastatic Colorectal
Found 6 free book(s)Clinical Practice Guidelines in Oncology (NCCN Guidelines ...
www2.tri-kobe.orgmetastatic colorectal cancer. J Clin Oncol 2009;27:672-80. Tol J, Koopman M, Cats A, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009;360(6):563-572. Infusional 5-FU is preferred. Patients with diminished creatinine clearance may require dose modification of capecitabine.
Chemotherapy Protocol COLORECTAL CANCER …
www.uhs.nhs.uk• First / second line treatment of advanced / metastatic colorectal cancer. • Adjuvant treatment of stage III colon cancer following surgery. • WHO Performance status 0, 1 Toxicity Drug Adverse Effect Fluorouracil Palmar-plantar erythrodysesthesia, diarrhoea, mucositis, chest pain ...
HIGHLIGHTS OF PRESCRIBING INFORMATION ERBITUXsafely …
pi.lilly.commetastatic colorectal cancer (mCRC) as determined by an FDA-approved test [see Dosage and Administration (2.2)]: • in combination with FOLFIRI (irinotecan, fluorouracil, leucovorin) for first-line treatment, • in combination with irinotecan in patients who are refractory to …
BC Cancer Protocol Summary for Palliative Combination ...
www.bccancer.bc.caFirst line therapy for locally advanced, locally recurrent or metastatic colorectal adenocarcinoma, not curable with surgery or radiation, and for adenocarcinoma of the appendix and small bowel.
YERVOY U.S. Prescribing Information
packageinserts.bms.comMetastatic Colorectal Cancer: YERVOY (ipilimumab) 1 mg/kg intravenously over 30 minutes immediately following nivolumab 3 mg/kg intravenously over 30 minutes on the same day, every 3 weeks for 4 doses. After completing 4 doses of the combination, administer nivolumab as a single agent as recommended in Full Prescribing Information for nivolumab.
Press Release
www.daiichisankyo.comDec 23, 2021 · Metastatic Breast Cancer In clinical studies, of the 234 patients with unresectable or metastatic HER2-positive breast cancer treated with ENHERTU 5.4 mg/kg, ILD occurred in 9% of patients. Fatal outcomes due to ILD and/or pneumonitis occurred in 2.6% of patients treated with ENHERTU. Median time to first onset was 4.1 months (range: 1.2 to 8.3).